Assess whether scientific advice should be sought before the next trial

SITUATION After a CRL citing manufacturing, not efficacy, biosimilar analytical similarity report is what CMC change-control owner can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after a CRL citing manufacturing, not efficacy. 2. Keep Pause the pathway in force until biosimilar analytical similarity report is completed after a CRL citing manufacturing, not efficacy for CMC change-control owner. 3. Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after a CRL citing manufacturing, not efficacy. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision scientific advice should be turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 3. Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for CMC change-control owner.

RECOMMENDATION CMC change-control owner owns scientific advice should be on biosimilar analytical similarity report in a mid-size sponsor after a complete response letter. After a CRL citing manufacturing, not efficacy, choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using only what this Pharma & Life Sciences Pharmacovigilance packet proves. If biosimilar analytical similarity report is silent on the discriminator after a CRL citing manufacturing, not efficacy, CMC change-control owner must state the unresolved clinical or safety evidence requirement explicitly rather than reuse a label from another Pharmacovigilance packet.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in biosimilar analytical similarity report, then the action for CMC change-control owner - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - What changes scientific advice should be if a CRL citing manufacturing, not efficacy is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others